Lilly Ventures
Seed–Late Stage
What they invest in
from 8 of 8 portfolio companiesBiotech ×8Deep Tech ×2Healthtech ×2Hardware ×1
HQs:United States×8
Investments · 8 tracked
founders shown can be your intro pathBy year:2025 · 12017 · 12016 · 12015 · 14 dated
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersJJDCStarfish Ventures
BiotechCharlottesville, US
TIMOTHY MACDONALD(Executive Officer)Anne Heldreth(Executive Officer)Andrew J Krouse(Executive Officer, Director)LLOYD GRAY(Executive Officer)
BoardHenry Skinner(Director)Sergei Petukhov(Director)
Co-investorsNovartis Venture Fund
BiotechIndianapolis, US
Steven E Hall(Executive Officer, Director)
BoardRichard Miller(Director)S Edward Torres(Executive Officer)Richard Kent(Director)
BiotechCambridge, US
Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)
BoardVincent Miles(Director)Jean George(Director)
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)Bernard Davitian(Director)
Co-investorsAtlas VentureHatteras Venture PartnersRoche Venture Fund
Quarry Thera is a biotech developing oral small-molecule medicines based on induced-proximity pharmacology, using molecular glues and heterobifunctional compounds.
BiotechDeep TechNew Haven, US
Craig Crews(Co-Founder & Scientific Advisor)inDan McHugh(Manager)Tim Shannon(CEO and Board Member)inJeanne Magram(Chief Scientific Officer)inKanak Raina(Chief Technology Officer)inSean Cassidy(Chief Financial Officer)in
Co-investorsYosemiteF-Prime CapitalCanaan Partners
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
Co-investorsLAVLilly Asia VenturesVivo Capital
Biotechnology company developing therapeutics that target the extracellular matrix in acute and chronic diseases.
BiotechSan Francisco, US
KENNETH N. HORNE(Executive Officer, Director)ALYSSA PANITCH(Director)JOHN PADERI(Director)KATE STUART(Executive Officer)
Co-investorsMitsui Global InvestmentAlly Bridge GroupInCube Ventures
Exits · 1
IPOs and acquisitions across the tracked portfolioProtagonist TherapeuticsNASDAQ: PTGX
Portfolio news
latest coverage across their companiesProtagonist Therapeutics · sahmcapital.com · Aug 6, 2026
Cavion · dailyprogress.com · May 11, 2026
Quarry Thera · castleplacement.com · Jan 8, 2026
Frequently asked questions
- What stage does Lilly Ventures invest at?
- Lilly Ventures invests at the Seed, Late Stage stages.
Similar investors
83North is a global venture capital firm that invests in and helps entrepreneurs build large, category-defining companies, backing startups across multiple stages and sectors.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Accel is a venture capital firm that partners with exceptional teams, positioning itself as a first partner to founders globally.
AirTree Ventures runs Pathfinders, a free four-week in-person program in Sydney for young builders (high-school graduates up to age 23) to work on a real product, access the AirTree team and founders, and build a peer network.